Document is current
Any future updates will be listed below
-
Authors
Halder, Kuntal
Borazanci, Erkut H.
Jameson, Gayle S.
Lin, Wei
Vrana, Amber
Cridebring, Derek
Tsai, Susan
Aldakkak, Mohammed
Evans, Douglas B.
Hayashi, Masamichi
Tanaka, Haruyoshi
Kanda, Mitsuro
Goel, Ajay https://orcid.org/0000-0003-1396-6341
Von Hoff, Daniel D. https://orcid.org/0000-0003-4723-7681
Han, Haiyong https://orcid.org/0000-0001-9031-9880
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA214254, U01CA214254, U01CA214254)
Flinn Foundation
the Dorrance Family Fund
HonorHealth Foundation
the Dorrance Family Fund, the Marley Foundation, the Seena Magowitz Foundation, Purple Pansies, John E. Sabga Foundation, the TGen Pancreatic Cancer National Advisory Council
- License Information
-
More Information
Article History
Received: 10 March 2025
Revised: 23 July 2025
Accepted: 13 August 2025
First Online: 3 September 2025
Competing interests
: HH is a SAB member of Stromatis Pharma and a consultant for ImproveBio. He also receives research funding from Avicenna Biosciences, Exact Therapeutics, and Minneamrita Therapeutics. DVH has stock and other ownership interests in Medtronic, CerRx, SynRevRx, United Healthcare, Anthem Inc., Stromatis Pharma, Systems Oncology, Stingray Therapeutics, Orpheus Bioscience, AADi, Origin Commercial Advisors, Halia Therapeutics, Lycia Therapeutics, (3 + 2) Pharma, AcuViz; Consulting or advisory role at ImagingEndpoints, CanBas, Lixte Biotechnology, TD2, Phosplatin Therapeutics, SOTIO, Immunophotonics, Oncology Venture, Novita Pharmaceuticals, Vicus Therapeutics, AiMed, Erimos Pharmaceuticals, Pfizer, ImmuneOncia, Viracta Pharmaceuticals, AlaMab Therapeutics, Xerient, Lycia Therapeutics, EXACT Therapeutics, ImaginAb, Signablok, Compass Therapeutics, Sellas Life Sciences, Catamaran Bio, SMP Oncology fka SDP/Tolero, Red Arrow Therapeutics, Soley Therapeutics, Invios GmbH, Mekanistic Therapeutics, POINT Biopharma, Remunity, SIWA Therapeutics, Xenthera, Indaptus fka Decoy, Panavance Therapeutics fka Feistlich, CyMon Bio, Bryologyx, Moleculin Biotech, EnGeneIC, Race Oncology, Autonomix, Econic Biosciences, Crinetics Pharmaceuticals, Diakonos Research, Improve Bio, Duo Oncology, ImmuVia, WUGEN, Inc., and Origin Commercial Advisors. Research funding from Lilly, Genentech, Celgene, Incyte, Merrimack, Plexxikon, Minneamrita Therapeutics, Abbvie, Aduro Biotech, Cleave Bioscience, CytRx Corporation, Daiichi Sankyo, Deciphera, Endocyte, Exelixis, Five Prime Therapeutics, Gilead Sciences, Merck, Pfizer, Pharmacyclics, Phoenix Biotech, Samumed, Strategia, and Halozyme. The rest of the authors declare that they have no competing interests.
: The collection of blood samples and clinical data used in this study was performed in accordance with the Declaration of Helsinki and was approved by the Institutional Review Boards (IRBs) of Translational Genomics Research Institute (WCG IRB), City of Hope (City of Hope IRB), HonorHealth Research Institute (HonorHealth IRB), Medical College of Wisconsin (MCW IRB), and Nagoya University School of Medicine (Nagoya University IRB). Consent was obtained from each participating subject.
